CD57 in human natural killer cells and T-lymphocytes
H Kared, S Martelli, TP Ng, SLF Pender… - Cancer Immunology …, 2016 - Springer
The CD57 antigen (alternatively HNK-1, LEU-7, or L2) is routinely used to identify terminally
differentiated 'senescent'cells with reduced proliferative capacity and altered functional …
differentiated 'senescent'cells with reduced proliferative capacity and altered functional …
[HTML][HTML] CD57 in human natural killer cells and T-lymphocytes
H Kared, S Martelli, TP Ng, SLF Pender… - Cancer Immunology …, 2016 - ncbi.nlm.nih.gov
The CD57 antigen (alternatively HNK-1, LEU-7, or L2) is routinely used to identify terminally
differentiated 'senescent'cells with reduced proliferative capacity and altered functional …
differentiated 'senescent'cells with reduced proliferative capacity and altered functional …
CD57 in human natural killer cells and T-lymphocytes
H Kared, S Martelli, TP Ng… - Cancer Immunology …, 2016 - search.proquest.com
The CD57 antigen (alternatively HNK-1, LEU-7, or L2) is routinely used to identify terminally
differentiated'senescent'cells with reduced proliferative capacity and altered functional …
differentiated'senescent'cells with reduced proliferative capacity and altered functional …
CD57 in human natural killer cells and T-lymphocytes
H Kared, S Martelli, TP Ng… - Cancer immunology …, 2016 - pubmed.ncbi.nlm.nih.gov
The CD57 antigen (alternatively HNK-1, LEU-7, or L2) is routinely used to identify terminally
differentiated'senescent'cells with reduced proliferative capacity and altered functional …
differentiated'senescent'cells with reduced proliferative capacity and altered functional …
CD57 in human natural killer cells and T-lymphocytes
H Kared, S Martelli, TP Ng, SLF Pender… - Cancer Immunology …, 2016 - infona.pl
The CD57 antigen (alternatively HNK-1, LEU-7, or L2) is routinely used to identify terminally
differentiated 'senescent'cells with reduced proliferative capacity and altered functional …
differentiated 'senescent'cells with reduced proliferative capacity and altered functional …
[引用][C] CD57 in human natural killer cells and T-lymphocytes
H Kared, S Martelli, TP Ng, SLF Pender… - Cancer Immunology …, 2016 - cir.nii.ac.jp
CD57 in human natural killer cells and T-lymphocytes | CiNii Research CiNii 国立情報学研究所
学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
CD57 in human natural killer cells and T-lymphocytes.
H Kared, S Martelli, T Ng, S Pender… - Cancer Immunology …, 2016 - search.ebscohost.com
The CD57 antigen (alternatively HNK-1, LEU-7, or L2) is routinely used to identify terminally
differentiated'senescent'cells with reduced proliferative capacity and altered functional …
differentiated'senescent'cells with reduced proliferative capacity and altered functional …
CD57 in human natural killer cells and T-lymphocytes
H Kared, S Martelli, TP Ng, SLF Pender… - Cancer Immunology …, 2016 - eprints.soton.ac.uk
The CD57 antigen (alternatively HNK-1, LEU-7, or L2) is routinely used to identify terminally
differentiated 'senescent'cells with reduced proliferative capacity and altered functional …
differentiated 'senescent'cells with reduced proliferative capacity and altered functional …
CD57 in human natural killer cells and T-lymphocytes.
H Kared, S Martelli, TP Ng, SL Pender… - Cancer Immunology …, 2016 - europepmc.org
The CD57 antigen (alternatively HNK-1, LEU-7, or L2) is routinely used to identify terminally
differentiated 'senescent'cells with reduced proliferative capacity and altered functional …
differentiated 'senescent'cells with reduced proliferative capacity and altered functional …
CD57 in human natural killer cells and T-lymphocytes.
H Kared, S Martelli, TP Ng, SL Pender… - Cancer Immunology …, 2016 - europepmc.org
The CD57 antigen (alternatively HNK-1, LEU-7, or L2) is routinely used to identify terminally
differentiated'senescent'cells with reduced proliferative capacity and altered functional …
differentiated'senescent'cells with reduced proliferative capacity and altered functional …